Arginine 104 Is a Key Catalytic Residue in Leukotriene C₄ Synthase*

Received for publication, February 9, 2010, and in revised form, September 28, 2010. Published, JBC Papers in Press, October 27, 2010, DOI 10.1074/jbc.M110.105940

Agnes Rinaldo-Matthias†, Anders Wetterholm†, Daniel Martinez Molina‡, Johanna Holm§, Damian Niegowski¶, Eva Ohlson†, Pär Nordlund‡, Ralf Morgenstern§, and Jesper Z. Haeggström††

From the Divisions of †Chemistry 2 and ‡Biophysics, Department of Medical Biochemistry and Biophysics, and §Institute of Environmental Medicine, Karolinska Institutet, S-171 77 Stockholm, Sweden

Human leukotriene C₄ synthase (hLTC₄S) is an integral membrane enzyme that conjugates leukotriene (LT) A₄ with glutathione to form LTC₄, a precursor to the cysteinyl leukotrienes (LTC₄, LTD₄, and LTE₄) that are involved in the pathogenesis of human bronchial asthma. From the crystal structure of hLTC₄S, Arg-104 and Arg-31 have been implicated in the conjugation reaction. Here, we used site-directed mutagenesis, UV spectroscopy, and x-ray crystallography to examine the catalytic role of Arg-104 and Arg-31. Exchange of Arg-104 with Ala, Ser, Thr, or Lys abolished 94.3–99.9% of the specific activity against LTA₄. Steady-state kinetics of R104A and R104S revealed that the Kₘ for GSH was not significantly affected. UV difference spectra of the binary enzyme-GSH complex indicated that GSH ionization depends on the presence of Arg-104 because no thiolate signal, with λₘₐₓ at 239 nm, could be detected using R104A or R104S hLTC₄S. Apparently, the interaction of Arg-104 with the thiol group of GSH reduces its pKₐ to allow formation of a thiolate anion and subsequent nucleophilic attack at C₆ of LTA₄. On the other hand, exchange of Arg-31 with Ala or Glu reduced the catalytic activity of hLTC₄S by 88 and 70%, respectively, without significantly affecting the Kₘ/Sₘ values for GSH, and a crystal structure of R31Q hLTC₄S (2.1 Å) revealed a Gln-31 side chain pointing away from the active site. We conclude that Arg-104 plays a critical role in the catalytic mechanism of hLTC₄S, whereas a functional role of Arg-31 seems more elusive. Because Arg-104 is a conserved residue, our results pertain to other homologous membrane proteins and represent a structure-function paradigm probably common to all microsomal GSH transferases.

Human leukotriene C₄ synthase (hLTC₄S)² is a 17-kDa integral membrane-bound enzyme that catalyzes the formation of potent smooth muscle-contracting mediators, the cysteinyl leukotrienes, leukotriene (LT) C₄ ((5S)-hydroxy-(6R)-S-glutathionyl-7,9-trans-11,14-cis-eicosatetraenoic acid) and its metabolites LTD₄ ((5S)-hydroxy-(6R)-S-cysteinylglycyl-7,9-trans-11,14-cis-eicosatetraenoic acid) and LTE₄ ((5S)-hydroxy-(6R)-S-cysteinyl-7,9-trans-11,14-cis-eicosatetraenoic acid). The cysteinyl leukotrienes elicit their effects through binding to the cysteinyl leukotriene receptors (1, 2), inducing bronchial smooth muscle contraction, permeability changes in the microcirculation, and immune modulatory actions. The role of cysteinyl leukotrienes in bronchial asthma was established by the therapeutic benefits observed after treatment with inhibitors of the biosynthetic pathway or receptor antagonist (reviewed in Refs. 3 and 4). The formation of LTC₄ catalyzed by hLTC₄S is localized to the outer nuclear membrane. The enzyme conjugates the unstable fatty acid epoxide LTA₄ ((5S)-trans-5,6-oxido-7,9-trans-11,14-cis-eicosatetraenoic acid) and GSH to form LTC₄ (see Fig. 1, left). hLTC₄S is expressed mainly in leukocytes, and targeted disruption of hLTC₄S in mouse showed reduced antigen-induced inflammation in lung cells (5, 6).

LTC₄S is a member of the MAPEG (membrane-associated proteins in eicosanoid and glutathione metabolism) superfamily of integral membrane proteins (7). This family has six human members and includes three proteins involved in detoxification (MGST1 (microsomal GSH S-transferase 1), MGST2, and MGST3) and three proteins with pivotal functions in specific biosynthetic pathways of arachidonic acid metabolism, viz. FLAP (five-lipoxygenase-activating protein), LTC₄S, and mPGES-1 (microsomal prostaglandin E synthase 1) (8–12). Probably all MAPEG members, except FLAP, which appears to lack enzymatic function, use a similar mechanism to conjugate glutathione to the lipophilic substrates. Structurally, all but MGST2 and MGST3 have been studied, and mechanistically, MGST1 has been subjected to thorough studies with regard to both substrate preferences and catalytic mechanism (13–15). MGST1 is involved in detoxification of xenobiotic substances by conjugation of GSH to electrophilic compounds (15). MGST2 and MGST3 are thought to have similar catalytic properties as MGST1, although MGST2 has also been shown to be able to produce LTC₄ (8, 11), but have not yet been assigned any specific function. mPGES-1 catalyzes the oxidoreduction of prostaglandin H₂ into prostaglandin E₂ and displays low glutathione transference and glutathione-dependent peroxidase activities (16). hLTC₄S is highly substrate-specific compared with the other MAPEG family members or GSH transferases, as it accepts only LTA₄, LTC₄, LTD₄, and LTE₄.
methyl ester, and, to a small extent, analog leukotriene epoxides (17, 18).

We previously solved the crystal structure of hLTC₄S, revealing a trimeric membrane protein (19). In this study, we wanted to investigate the contribution to catalysis of individual residues at the active site of hLTC₄S, and in particular, we wanted to understand the role of Arg-104 during catalysis. Arg-104 has been suggested to activate the GSH thiol and stabilizing the resultant thiolate anion.

From the crystal structure solved to 2.2 Å (19), the active site of hLTC₄S is well defined with regard to GSH binding. GSH is coordinated to eight residues from two subunits of the trimer (see Fig. 1, right), several of which are conserved among members of the MAPEG family (21). The guanidinium group of Arg-104 interacts with the –SH group of GSH at a distance of 3.2 Å, and Arg-104 was therefore suggested to be involved in lowering the pKₐ of the thiol proton (19).

In this study, we used site-directed mutagenesis, UV spectroscopy, and x-ray crystallography to investigate the catalytic roles of active-site residues Arg-31, Arg-51, Tyr-59, and Arg-104 in hLTC₄S. In particular, we show that Arg-104, but not Arg-31, plays a key role in the enzyme mechanism by activating the GSH thiol and stabilizing the resultant thiolate anion.

EXPERIMENTAL PROCEDURES

Materials—Imidazole, Tris base, NaCl, KCl, Triton X-100, sodium deoxycholate, S-hexylglutathione-agarose, probenecid, GSH, and 2-mercaptoethanol were obtained from Sigma. Platinum Pfx DNA polymerase and deoxyribonucleotides were from Invitrogen. Dodecyl maltoside was obtained from Anatrace. LTA₄ methyl ester (BIOMOL) in tetrahydrofuran was saponified with 1 M LiOH (6%, v/v) for 48 h at 4 °C. All other chemicals were obtained from common commercial sources.

Site-directed Mutagenesis—The hLTC₄S cDNA (I.M.A.G.E. cDNA clone 5277851, Medical Research Council Geneservice, Cambridge, United Kingdom) was subcloned into pPICZa (Invitrogen). Both the cDNA, supplemented with a N-terminal sequence encoding a His₆ tag, and the vector were PCR-amplified, and the products were co-transformed into CaCl²-treated E. coli TOP10 (TIENTOP, Invitrogen), using the endogenous recombinase activity of E. coli to recombine the fragments. Site-directed mutagenesis was carried out according to the QuikChange protocol (Stratagene, La Jolla, CA).

The primers were as follows: 5'-cgcgctgcagtctgtgacgctg-3' and 5'-cagcgtgctagctgcagcgg-3' for R104S; 5'-caccgcaagtctggtcgaggtc-3' for R104A; 5'-gctgcaagtctggtcgaggtc-3' and 5'-caccgcaagtctggtcgaggtc-3' for R104K; 5'-ctcagctgtcaagctgcagcgg-3' and 5'-ctcagctgtcaagctgcagcgg-3' for R104T; 5'-cgcgctgcagtctggtcgaggtc-3' and 5'-cgcgctgcagtctggtcgaggtc-3' for R104Q; 5'-cgcgctgcagtctggtcgaggtc-3' and 5'-cgcgctgcagtctggtcgaggtc-3' for R104H; and 5'-cgcgctgcagtctggtcgaggtc-3' and 5'-cgcgctgcagtctggtcgaggtc-3' for R104N.

The enzyme used for spectroscopic studies was, after the QuikChange protocol, immobilized metal ion affinity chromatography step, purified in buffers containing 0.03% (w/v) dodecyl maltoside and 0.1 M NaCl, followed by an additional wash with buffer A containing 40 mM imidazole and 0.5 M NaCl. hLTC₄S was eluted with 300 mM imidazole, 0.1 M NaCl, followed by an additional wash with buffer A containing 40 mM imidazole and 0.5 M NaCl. hLTC₄S was eluted with 300 mM imidazole, 0.1 M NaCl, and 0.1 M GSH in buffer A. The final step of purification was performed on a column packed with S-hexylglutathione-agarose. The column was washed with buffer A supplemented with 0.5 M NaCl and 0.1 mM GSH. Pure hLTC₄S was eluted with 25 mM Tris-HCl (pH 7.8), 10% glycerol, 0.1% Triton X-100, and 5 mM 2-mercaptoethanol supplemented with 20 mM imidazole and 0.1 M NaCl, followed by an additional wash with buffer A containing 300 mM imidazole and 0.5 M NaCl and 0.1 mM GSH in buffer A. The final step of purification was performed on a column packed with S-hexylglutathione-agarose. The column was washed with buffer A supplemented with 0.5 M NaCl and 0.1 mM GSH. Pure hLTC₄S was eluted with 25 mM Tris-HCl (pH 7.8), 10% glycerol, 0.05% Triton X-100, and 0.1 mM GSH. The sample was desalted on PD-10 columns (GE Healthcare) and eluted in 25 mM Tris-HCl (pH 7.8), 10% glycerol, 0.05% Triton X-100, and 0.1 mM GSH. After a 5-fold concentration on an Amicon Ultra-15 centrifugal filter device (Millipore), the purified protein was stored frozen at −20 °C.

The enzyme used for spectroscopic studies was, after the immobilized metal ion affinity chromatography step, purified in buffers containing 0.03% (w/v) dodecyl maltoside and 0.1 M NaCl, followed by an additional wash with buffer A containing 40 mM imidazole and 0.5 M NaCl. hLTC₄S was eluted with 300 mM imidazole, 0.1 M NaCl, and 0.1 M GSH in buffer A. The final step of purification was performed on a column packed with S-hexylglutathione-agarose. The column was washed with buffer A supplemented with 0.5 M NaCl and 0.1 mM GSH. Pure hLTC₄S was eluted with 25 mM Tris-HCl (pH 7.8), 10% glycerol, 0.1% Triton X-100, and 5 mM 2-mercaptoethanol supplemented with 20 mM imidazole and 0.1 M NaCl, followed by an additional wash with buffer A containing 40 mM imidazole and 0.5 M NaCl. hLTC₄S was eluted with 300 mM imidazole, 0.1 M NaCl, and 0.1 M GSH in buffer A. The final step of purification was performed on a column packed with S-hexylglutathione-agarose. The column was washed with buffer A supplemented with 0.5 M NaCl and 0.1 mM GSH. Pure hLTC₄S was eluted with 25 mM Tris-HCl (pH 7.8), 10% glycerol, 0.05% Triton X-100, and 0.1 mM GSH. After a 5-fold concentration on an Amicon Ultra-15 centrifugal filter device (Millipore), the purified protein was stored frozen at −20 °C.

The enzyme used for spectroscopic studies was, after the immobilized metal ion affinity chromatography step, purified in buffers containing 0.03% (w/v) dodecyl maltoside and 0.1 M NaCl, followed by an additional wash with buffer A containing 40 mM imidazole and 0.5 M NaCl. hLTC₄S was eluted with 300 mM imidazole, 0.1 M NaCl, and 0.1 M GSH in buffer A. The final step of purification was performed on a column packed with S-hexylglutathione-agarose. The column was washed with buffer A supplemented with 0.5 M NaCl and 0.1 mM GSH. Pure hLTC₄S was eluted with 25 mM Tris-HCl (pH 7.8), 10% glycerol, 0.05% Triton X-100, and 0.1 mM GSH. After a 5-fold concentration on an Amicon Ultra-15 centrifugal filter device (Millipore), the purified protein was stored frozen at −20 °C.

Activity Measurements—To determine the enzyme activity, aliquots of enzyme (0.2 μg for wild-type, R51A, R51Q, Y59F, and R31Q hLTC₄S and 0.3–10 μg for R104A, R104T, R104K, R104S, and R31A hLTC₄S) were diluted to 100 μl with 25 mM Tris-HCl (pH 7–9.1) supplemented with 0.03% Triton X-100.
and 5 mM GSH. The incubations were performed at room temperature with 30 μM LTA₄ and stopped after 15 s by the addition of 200 μL of methanol followed by 100 μL of water. Prostaglandin B₂ (400–500 pmol) was added as an internal standard before reversed phase-HPLC, which was performed on a Waters Nova-Pak C₁₈ column (3.9 × 150 mm) eluted with a mixture of acetonitrile/methanol/water/acetic acid (30:20:50:0.1, v/v/v) at an apparent pH 5.6 and at a flow rate of 0.8 ml/min (LKB 2150 pump). Qualitative analysis was performed by comparison with the retention time of synthetic LTC₄ and the UV absorbance of eluted compounds at 280 nm using a Milton Roy SpectroMonitor 3100 detector. The amount of LTC₄ was quantified by calculating the ratio of the peak area compared with the internal standard prostaglandin B₂.

The kₐ₅ and kᵢₜ values were determined from the initial velocity of the hLTC₄S-catalyzed reaction measured as a function of substrate (GSH) concentration. The initial velocity data were fitted to the Michaelis-Menten equation using GraphPad Prism. The kₐ₅ value was calculated from the V₉₅max and enzyme concentration ([E]) according to equation kₐ₅ = V₉₅max/[E] (see Table 2).

Ultraviolet Difference Spectroscopy—UV spectra were recorded on a Philips PU8720 or Cary 400 Bio spectrophotometer at room temperature. Spectrum (200–400 nm) were recorded in 1-cm cuvettes with WT, R104A, and R104S hLTC₄S (20 μM) in 100 mM Tris-Cl (pH 7.2) with 0.05% dodecyl maltoside in the presence or absence of 0.5 mM GSH. Difference spectra were obtained by subtracting the spectra of enzyme in buffer without GSH and in buffer with 0.5 mM GSH. The formation of a thiolate anion was measured as an increase in absorbance at 239 nm with ε₂₃₉ = 5000 M⁻¹ cm⁻¹ (22, 23). Each measurement was repeated at least three times using three different protein batches. The same experiment was performed with 1 mM GSO₃⁻ added to the cuvette with hLTC₄S-GS⁻, with GSO₃⁻ acting as a competitive inhibitor.

Crystallization of R31Q hLTC₄S—Crystals of R31Q hLTC₄S were grown and cryo-cooled as described (19). Diffraction data were collected to a resolution of 2.1 Å for the complex at 20%, respectively. The quality of the final structure was verified using PROCHECK (28). The Ramachandran plot for the R31Q hLTC₄S structure showed that 97% of residues were in the most favorable regions and 2% were in the allowed region. The coordinates and structure factors for R31Q hLTC₄S have been deposited in the Protein Data Bank (code 3LEO). All figures were made using PyMOL (Delano Scientific).

RESULTS AND DISCUSSION

We have studied the contribution of candidate catalytic residues at the active site of hLTC₄S to the enzyme’s ability to conjugate GSH with LTA₄. The two mechanistically oriented questions we wanted to answer were the possible role of Arg-104 in stabilizing the GSH thiolate anion and the possible role of Arg-31 during epoxide opening. The two residues were mutated, and steady-state kinetics was used to determine the catalytic behavior. UV difference spectroscopy was employed to analyze thiolate anion stabilization by Arg-104, and crystallography was used to study the structure of an Arg-31 mutant. In addition, we mutated and studied the functional roles of Arg-51 and Tyr-59 coordinating GSH at the active site of hLTC₄S.

Structural Evidence for the Involvement of Arg-104 in Catalysis—The first suggestions that Arg-104 might be involved in activating the thiol during catalysis of hLTC₄S arose when the structure was solved in 2007 (19, 20). The putative active site in the two crystal structures showed a bound GSH with the –SH group in close proximity to the guanidinium group of Arg-104 with a coordination distance of 3.2 Å (Fig. 1, right). Examining distances from other residues to the –SH group shows that there is no other good candidate that could activate the thiol.

Mutants of Arg-104—To determine the role of Arg-104 in the formation of the thiolate anion during the hLTC₄S conjugation reaction, we mutated Arg-104 to Ala, Ser, Thr, and Lys in separate constructs. The plasmids were transformed into P. pastoris cells, and the proteins were expressed and purified using nickel-agarose and S-hexylglutathione affinity column chromatography. The ability of the enzymes to bind GSH appeared not to be impaired because they could still be purified using one step of S-hexylglutathione affinity chromatography. Effects of Mutations on Enzyme Activity—All of the Arg-104 mutations strongly reduced the ability of hLTC₄S to form LTC₄ as measured by HPLC. The amount of LTC₄ generated by R104A, R104S, R104T, and R104K was so low that, to achieve quantitative data, the amount of protein used in the incubations was increased from 0.2 μg for the WT enzyme to 0.5, 0.6, 6, and 10 μg for the mutants, respectively. Under
Arg-104 Is a Key Residue in hLTC₄S

**TABLE 1**

Specific activity of wild-type and mutant hLTC₄S with 5 mM GSH (pH 7.8) and 30 μM LTA₄

| Enzyme | Specific activity | % of WT |
|--------|------------------|---------|
| WT     | 35 ± 0.5 μmol/min mg | 100     |
| R104A  | 2.0 ± 0.2         | 5.7     |
| R104S  | 1.6 ± 0.3         | 4.6     |
| R104K  | 0.04 ± 0.02       | 0.1     |
| R104T  | 0.4 ± 0.1         | 1.1     |
| R31Q   | 10.5 ± 5.9        | 30      |
| R31A   | 4.3 ± 0.2         | 12      |
| R51A   | 20 ± 5            | 57      |
| R51Q   | 10 ± 2            | 29      |

Table 2. Specific activity of wild-type and mutant hLTC₄S with 5 mM GSH (pH 7.8) and 30 μM LTA₄

| Enzyme | Specific activity | % of WT |
|--------|------------------|---------|
| WT     | 35 ± 0.5 μmol/min mg | 100     |
| R104A  | 0.5 ± 0.1         | 1.1     |
| R104S  | 0.1 ± 0.01        | 0.06    |
| R104K  | 0.04 ± 0.02       | 0.1     |
| R104T  | 0.4 ± 0.1         | 1.1     |
| R31Q   | 10.5 ± 5.9        | 30      |
| R31A   | 4.3 ± 0.2         | 12      |
| R51A   | 20 ± 5            | 57      |
| R51Q   | 10 ± 2            | 29      |

**FIGURE 2. Steady-state kinetic analysis of WT hLTC₄S and Arg-104 mutants.** Shown is the specific activity of WT (0.2 μg), R104A (0.5 μg), and R104S (0.6 μg) hLTC₄S, where LTA₄ was kept constant at 30 μM and GSH was varied between 0.01 and 5 mM.

These experimental conditions, the percent of the specific activities of the different batches of R104A, R104S, R104T, and R104K compared with the WT enzyme were 5.7, 4.5, 1, and 0.1%, respectively (Table 1). The mutant proteins were subjected to extensive crystallization efforts, in particular, R104A and R104S hLTC₄S. Although the proteins yielded crystals, they diffracted to only ~8–10 Å and thus did not allow structural analysis. However, rescue of the enzyme activity of the mutants by increased pH and their ability to bind the affinity column strongly indicate that the mutations had not introduced any significant conformational changes at the active sites (see below).

The small residual activity of R104A and R104S, in which the side chains are considerably shorter, may be explained by increased space for water molecules that can aid in hydroxyl anion-assisted thiolate formation, in line with our experimental observations (see Fig. 3b). In the Lys mutant, which has a markedly lower activity, there is little (if any) room for water, and the different structure of the side chain is likely to change the position of the positive charge. In summary, 94.3–99.9% of the activity observed for the wild-type enzyme could be abolished by a single point mutation of Arg-104.

Steady-state kinetics of the R104A and R104S mutants at saturating concentrations of LTA₄ (30 μM) showed a decreased Vₘₐₓ but a relatively similar Kₘ for GSH (Fig. 2 and Table 2). The retained Kₘ for GSH in agreement with results obtained from the purification procedure (i.e. the mutants bound to an S-hexylglutathione affinity column).

**TABLE 2**

Steady-state kinetic parameters of hLTC₄S obtained at 20 °C and pH 7.8 during incubation for 15 s

In the respective measurements, 0.2 μg of WT, 0.5 μg of R104A, 0.6 μg of R104S, 0.4 μg of R31Q, and 1 μg of R31A hLTC₄S were used.

| Enzyme | kₘ | Vₘₐₓ | kₘ/Vₘₐₓ | kₘ/kₘ/Vₘₐₓ |
|--------|-----|------|----------|-------------|
| WT     | 0.3 | 35   | 2        | 17.7        |
| R104A  | 0.5 | 2    | 0.2      | 1.3         |
| R104S  | 0.1 | 1.6  | 0.3      | 5           |
| R31Q   | 0.07| 5.5  | 0.1      | 18          |
| R31A   | 0.05| 4.3  | 0.2      | 14          |

Ionization of GSH Bound to hLTC₄S—To detect the presence of the thiolate anion, analyses of UV difference spectra were performed. UV difference spectra of GSH bound to WT hLTC₄S were obtained by mixing 0.5 mM GSH with 20 μM hLTC₄S (0.35 mg/ml). Prior to mixing enzyme and GSH, the spectral contributions of free enzyme and free GSH were subtracted. The presence of thiolate was detected from the peak absorbance at 239 nm seen in the spectra from 200 to 300 nm (εthiolate = 5000 M⁻¹ cm⁻¹). The experiment was repeated three times with three different batches of enzyme, all yielding the same results. For simplicity, only one representative measurement is shown in Fig. 3a. The concentration of thiolate anion formed was calculated to be 17.3 ± 4.2 μM (mean ± S.D., n = 3) using the WT enzyme, which thus equaled the concentration of enzyme used in the experiment (20 μM), suggesting a 1:1 stoichiometry in the binding of thiolate to the enzyme (one thiolate/subunit). The same stoichiometry was obtained in pre-steady-state kinetics experiments measuring the rate of thiolate anion formation in hLTC₄S.³ It appears that hLTC₄S harbors three catalytically competent active sites/homotrimer, in contrast to MGST1, which displays one-third of the active sites reactive (29).

Analyses of UV difference spectra for R104A and R104S hLTC₄S failed to produce a visible thiolate at 239 nm, further corroborating the notion that Arg-104 is important for GSH activation. To ascertain that the peak observed at 239 nm for WT hLTC₄S was due to GS⁻ formation at the active site, we used a competitive inhibitor to GSH, viz. GSO₃⁻. This compound was incubated with WT hLTC₄S prior to mixing the enzyme with GSH, which completely prevented the appearance of a thiolate signal (Fig. 3a). Hence, a functional sulfhydryl group is needed, as well as a guanidinium group from Arg-104, to achieve a thiolate signal.

**pH Dependence of hLTC₄ Production**—The formation of the thiolate anion is considered a key step in GST catalysis (30). Because the sulfhydryl group of GSH is a weak acid with a pKₐ of 9 (23, 31), thiolate anions form spontaneously only at high pH. Accordingly, it should be possible to rescue some GSH-conjugating capacity from inactive mutants at higher pH if the bound GSH can form a thiolate by the influence of solvent pH. As depicted in Fig. 3b, the activity of the WT enzyme was not significantly increased when the pH was increased from 7.0 to 9.1. This suggests that the catalytic machinery had already reduced the activation energy of the conjugation reac-

³ A. Rinaldo-Matthis, J. Holm, A. Wetterholm, R. Morgenstern, and J. Z. Heggström, unpublished data.
zymes incubated with the competitive inhibitor (GSO$_3^-$), the thiolate formed at the active site is thought to conformations. Not caused any significant alterations of the protein rescued demonstrates that the amino acid substitutions have increased its ability to generate LTC$_4$ from 0.9% at pH 7.0 to 32% at pH 9.1, demonstrating that alkaline conditions can partially compensate for the loss of Arg-104. Of note, the fact that enzyme activity in R104A and R104S hLTC$_4$S could be rescued demonstrates that the amino acid substitutions have not caused any significant alterations of the protein conformations.

**Mutations of Arg-31**—During the catalytic reaction of hLTC$_4$S, the thiolate formed at the active site is thought to attack C6 of the oxirane ring of LTA$_4$ concomitant with the opening of the LTA$_4$ epoxide, leading to formation of a hydroxyl group at C5. It is reasonable to anticipate that a residue might participate in epoxide opening by stabilizing the developing negative oxygen. From the crystal structures of hLTC$_4$S, Arg-31 was suggested to serve this role (10, 11). Thus, it was speculated that Arg-31 would move closer to the epoxide of LTA$_4$ during catalysis and stabilize the negatively charged epoxide oxygen prior to the attack of the thiolate anion. However, in the crystal structures, Arg-31 is disordered and partially lacks electron density in the structures, making it difficult to determine its exact position and potential role in catalysis. To probe the function of Arg-31, we exchanged this residue with Ala or Gln. The R31Q and R31A mutants retained 30 and 12%, respectively, of the activity of WT hLTC$_4$S (see Table 1), suggesting that this residue does not have a crucial role during catalysis. Rather, the mutation of Arg-31 may introduce some smaller structural changes in the active-site region that influence binding of substrates. To further analyze the role of Arg-31, we solved the crystal structure of R31Q hLTC$_4$S in complex with GSH to 2.1 Å resolution (Table 3). The structure showed Arg-31 substituted with a defined electron density representing Gln-31 pointing away from the active site with a distance between its functional group and the GSH thiol of 7 Å (Fig. 4). To date, there is no structural evidence defining the exact position of the epoxide during catalysis because a structure of a product (LTC$_4$) complex and/or substrate (LTA$_4$) complex is missing. Pending more detailed structural and kinetic information on substrate binding, our data do not favor any specific role for Arg-31 in enzyme catalysis.

**Other Interactions with GSH**—Previous mutagenesis studies of Arg-51, with activity measurements in microsomal membranes, indicated that this residue has a crucial role in LTC$_4$ production (32). The data presented here on purified proteins

---

**TABLE 3**

**Data processing and refinement statistics of R31Q hLTC$_4$S in complex with GSH**

| r.m.s., root mean square; PDB, Protein Data Bank. |  |
|---|---|
| Wavelength (Å) | 0.93340 |
| Space group | F23 |
| Cell dimensions | a = b = c (Å) 170 |
| α = β = γ (°) 90° |
| Resolution (Å) | 2.1 |
| Unique reflections | 31,117 |
| All reflections | 221,628 |
| Completeness (%) | 99.1 (100) |
| Multiplicity | 7.1 (7.5) |
| R$_{free}$ (%) | 13.4 (40.6) |
| l(obs) | 20.8 (4.1) |
| No. of protein atoms | 1189 |
| No. of waters | 61 |
| No. of ligands | 12 |
| R-factor | 18 |
| R$_{free}$ | 20.4 |
| Average B-factor | 35 |
| r.m.s. bond (Å) | 0.018 |
| r.m.s. angle | 1.77° |
| Ramachandran analysis | Most favored regions 97.3 |
| Allowed regions | 2.0 |
| Disallowed regions | 0.7 |
| PDB code | 3LEO |

---

**FIGURE 3.** a, UV difference spectra of hLTC$_4$S. The blue trace shows the WT enzyme mixed with 0.5 mM GSH. The black trace corresponds to R104A hLTC$_4$S mixed with GSH. The red trace corresponds to R104S hLTC$_4$S mixed with GSH. The green trace is the WT enzyme mixed with 1 mM GSH and GSO$_3^-$. A UV scan from 200 to 400 nm shows that a thiolate anion gives rise to a peak at 239 nm in the spectrum of hLTC$_4$S but not in spectra from the mutant and WT enzymes incubated with the competitive inhibitor (GSO$_3^-$). b, the specific activity of hLTC$_4$S is compared with those of R104A, R104S, and R31Q hLTC$_4$S when the pH was changed between 7 and 9. The WT enzyme did not show pH dependence to the same extent as the R104A and R104S mutants. The non-enzymatic formation of LTC$_4$ did not reach detectable levels at any pH in buffer controls without enzyme.

**FIGURE 4.** Active site of the R31Q hLTC$_4$S structure where a 2F$_o$ − F$_c$ map electron density is contoured at 1σ. The protein is shown in cyan, and GSH is shown in green. DDM, dodecyl maltoside.
Arg-104 Is a Key Residue in LTC₄S

of mutants R51A and R51Q show a retained activity of 30–60% compared with the WT enzyme (Table 1), which suggests that Arg-51 is not essential for catalysis. In the crystal structure of hLTC₄S in complex with GSH, Arg-51 is coordinating one of the carboxyl groups of GSH with a distance of 2.9 Å in concert with Tyr-97 (Fig. 1, right). In agreement with previous results, Tyr-59 does not seem to be essential for catalysis because 90% of the activity is retained in Y59F hLTC₄S compared with the WT enzyme (data not shown). It is interesting to note that mutations of Tyr-59 and Arg-51, both of which are involved in GSH binding, have only small catalytic effects, suggesting that the GSH-binding mode is maintained in these mutations.

A Catalytic Arg Residue, a Common Theme among Microsomal GSTs—The enzymatic ability to lower the pKₐ of the sulffhydryl group of GSH is central for GSH-conjugating enzymes such as hLTC₄S. The thiol of GSH has a pyridyl group of GSH is central for GSH-conjugating enzymes mutations. suggesting that the GSH-binding mode is maintained in these enzymes.

Arg-104 Is a Key Residue in LTC₄S

Altered mPGES-1 activity will show whether it represents a structure-function paradigm common to all microsomal GSH transferases.

REFERENCES

1. Lynch, K. R., O’Neill, G. P., Liu, Q., Im, D. S., Sawyer, N., Metters, K. M., Coulombe, N., Abramovitz, M., Figueroa, D. J., Zeng, Z., Connolly, B. M., Bai, C., Austin, C. P., Chateauneuf, A., Stocco, R., Greig, G. M., Kargman, S., Hooks, S. B., Hosfield, E., Williams, D. L., Jr., Ford-Hutchinson, A. W., Caskey, C. T., and Evans, J. F. (1999) Nature 399, 789–793.

2. Heise, C. E., O’Dowd, B. F., Figueroa, D. J., Sawyer, N., Nguyen, T., Im, D. S., Stocco, R., Bellefeuille, J. N., Abramovitz, M., Cheng, R., Williams, D. L., Jr., Zeng, Z., Liu, Q., Ma, L., Clements, M. K., Coulombe, N., Liu, Y., Austin, C. P., George, S. R., O’Neill, G. P., Metters, K. M., Lynch, K. R., and Evans, J. F. (2000) J. Biol. Chem. 275, 30531–30536.

3. Peters-Golden, M., and Henderson, W. R., Jr. (2007) N. Engl. J. Med. 357, 1841–1854.

4. Rinaldo-Matthis, A., and Haeggstrom, J. Z. (2010) Biochimie 92, 676–681.

5. Beller, T. C., Maekawa, A., Friend, D. S., Austen, K. F., and Kanaoka, Y. (2004) J. Biol. Chem. 279, 46129–46134.

6. Kim, D. C., Hsu, F. I., Barrett, N. A., Friend, D. S., Greninglo¨h, R., Ho, L. C., Al-Garawi, A., Lora, J. M., Lam, B. K., Austen, K. F., and Kanaoka, Y. (2006) J. Immunol. 176, 4440–4448.

7. Jakobsson, P. J., Morgenstern, R., Mancini, J., Ford-Hutchinson, A., and Persson, B. (1999) Protein Sci. 8, 689–692.

8. Jakobsson, P. J., Mancini, J. A., Riendeau, D., and Ford-Hutchinson, A. W. (1997) J. Biol. Chem. 272, 22934–22939.

9. Samuelsson, B. (1983) Science 220, 568–575.

10. Ford-Hutchinson, A. W., Gresser, M., and Young, R. N. (1994) Annu. Rev. Biochem. 63, 383–417.

11. Jakobsson, P. J., Scoggan, K. A., Yergey, J., Mancini, J. A., and Ford-Hutchinson, A. W. (1997) J. Lipid Mediat. Cell Signal. 17, 15–19.

12. Jakobsson, P. J., Thörén, S., Morgenstern, R., and Samuelsson, B. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 7220–7225.

13. Morgenstern, R., and DePierre, J. W. (1983) Eur. J. Biochem. 134, 591–597.

14. Svensson, R., Alander, J., Armstrong, R. N., and Morgenstern, R. (2004) Biochemistry 43, 8869–8877.

15. Siritantikorn, A., Johansson, K., Ahlen, K., Rinaldi, R., Suthiphongchai, T., Wilairat, P., and Morgenstern, R. (2007) Biochem. Biophys. Res. Commun. 355, 592–596.

16. Thörén, S., Weinander, R., Saha, S., Jegerschöld, C., Pettersson, P. L., Samuelsson, B., Hebert, H., Hamberg, M., Morgenstern, R., and Jakobsson, P. J. (2003) J. Biol. Chem. 278, 22199–22209.

17. Izumi, T., Honda, Z., Ohishi, N., Kitamura, S., Tsuchida, S., Sato, K., Shimizu, T., and Seyama, Y. (1988) Biochim. Biophys. Acta 959, 305–315.

18. Yoshimoto, T., Soberman, R. J., Spur, B., and Austen, K. F. (1988) J. Clin. Invest. 81, 866–871.

19. Martinez Molina, D., Wetterholm, A., Kohl, A., McCarthy, A. A., Niegoswki, D., Ohlson, E., Hammarberg, T., Eshaghi, S., Haeggström, J. Z., and Nordlund, P. (2007) Nature 448, 613–616.

20. Ago, H., Kanaoka, Y., Irikura, D., Lam, B. K., Shimamura, T., Austen, K. F., and Miyano, M. (2007) Nature 448, 609–612.

21. Martinez Molina, D., Eshaghi, S., and Nordlund, P. (2008) Curr. Opin. Struct. Biol. 18, 442–449.

22. Graminski, G. F., Zhang, P. H., Sesay, M. A., Ammon, H. L., and Armstrong, R. N. (1989) Biochemistry 28, 6252–6258.

23. Graminski, G. F., Kubo, Y., and Armstrong, R. N. (1989) Biochemistry 28, 3562–3568.

24. Kabsch, W. (1988) J. Appl. Crystallogr. 21, 67–72.

25. Potterton, E., Briggs, P., Turkenburg, M., and Dodson, E. (2003) Acta Crystallogr. D Biol. Crystallogr. 59, 1131–1137.

26. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Acta Crystallogr. D Biol. Crystallogr. 53, 240–255.

27. Emsley, P., and Cowtan, K. (2004) Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132.

28. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) J. Appl. Crystallogr. 26, 283–291.

29. Alander, J., Lengqvist, J., Holm, P. J., Svensson, R., Gerbaux, P., Heuvel, R. H., Hebert, H., Griffiths, W. J., Armstrong, R. N., and Morgenstern, R. (2009) Arch. Biochem. Biophys. 487, 42–48.

30. Armstrong, R. N. (1997) Chem. Res. Toxicol. 10, 2–18.

31. Chen, W. J., Graminski, G. F., and Armstrong, R. N. (1988) Biochemistry 27, 647–654.

32. Lam, B. K. P., Penrose, J. F., Xu, K., Balasahar, M. H., and Austen, K. F. (1997) J. Biol. Chem. 272, 13923–13928.

33. Morgenstern, R., Svensson, R., Bernat, B. A., and Armstrong, R. N. (2001) Biochemistry 40, 3378–3384.

34. Holm, P. J., Bhakat, P., Jegerschöld, C., Goto, N., Matsuoka, K., Fujisawa, Y., Morgenstern, R., and Hebert, H. (2006) J. Mol. Biol. 360, 934–945.

35. Hammarberg, T., Hamberg, M., Wetterholm, A., Hansson, H., Samuelsson, B., and Haeggström, J. Z. (2009) J. Biol. Chem. 284, 301–305.

36. Caccuri, A. M., Antonini, G., Board, P. G., Flanagan, J., Parker, M. W., Paolese, R., Turella, P., Federici, G., Lo Bello, M., and Ricci, G. (2001) J. Biol. Chem. 276, 5427–5431.

37. Patkowski, Y. V., Patkowski, L. N., and Listowski, I. (2000) J. Biol. Chem. 275, 3296–3304.

40776 JOURNAL OF BIOLOGICAL CHEMISTRY

VOLUME 285 • NUMBER 52 • DECEMBER 24, 2010